GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of SURPASS — 14 things I got wrong before I got it right — 39 comments in the full submission. View in context.
1.1k
c/trialwatch·submitted 6 months ago by u/foam_head_fred

SURPASS — 14 things I got wrong before I got it right

Statsbranch of 6 comments

SURPASS — 14 things I got wrong before I got it right. Making the case below, and I expect to lose some of it in the comments. Quoted a figure here confidently, got asked whether it was ITT, went and checked, and it was not. Learned something. Spent an evening with the appendix tables and found the subgroup detail…

Read the full submission and all 39 comments →

This branch

6 comments, started 6 months ago
u/niels_norgaard130 points·6 months ago

Cardiovascular outcome trials are powered for events, not for weight, and are typically run in a different population with different inclusion criteria. Reading a weight number out of one is reading a secondary endpoint.

replysharereportpermalink
u/foam_head_fred63 points·6 months ago

Cardiovascular outcome trials are powered for events, not for weight, and are typically run in a different population with different inclusion criteri

niels_norgaard is right about the programme names. They are different populations with different endpoints.

replysharereportpermalink
u/customs_seizure_sid103 points·6 months ago

That is the 68-week readout, not the 72-week one. Different trial, different duration.

replysharereportpermalink
u/hamza_zielinski80 points·6 months ago

registry entry, protocol, publication — three different documents

replysharereportpermalink
u/rt_shift_reggie63 points·5 months ago

That is a relative risk reduction. Quoting it without the absolute numbers overstates the case considerably.

replysharereportpermalink
[removed]41 points·5 months ago

[removed by moderator]

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →